Leveragen is a Boston-based platform company advancing single-domain antibody (sdAb) discovery for a wide range of applications, including bispecifics, multispecifics, ADCs, CAR-T, mRNA therapeutics, research and diagnostics, as well as animal health. Leveragen’s proprietary platforms support streamlined, sequence-first, high-throughput discovery of highly diverse and developable sdAbs. The resulting clean, high-resolution datasets are ideally suited for AI-driven modeling, enabling the rapid development of next-generation biologics.